Ken X
Partner of VC Fund @ Ascentage Pharma
China
Xuhui District
Pharmaceuticals
Cancer Research, Translational Research, Molecular Biology, Cell Biology, Western Blotting
Experience

VP of BD and IR
Shanghai, China
LyncBio Therapeutics is a biotech company focused on innovation in next-gen ADC technology and pipeline. We have established a series of proprietary ADC platforms and developed a core asset for inflammatory bowel disease (IBD). LYNC-101 is our most advanced asset for target delivery and advanced therapy for IBD, which is advancing into Phase I clinical trial. LYNC-101 demonstrates superior preclinical efficacy in multiple IBD animal models and safety in rodents and NHP tox studies. LYNC-101 has the potential to be the first ADC drug treating IBD globally and next blockbuster drug for IBD. Meanwhile, LyncBio Therapeutics is also developing novel BsADCs at various development stages, covering both autoimmune diseases and oncology.

Senior Manager of Innovation Collaboration
China Innovation Hub at Merck Group
Shanghai/Guangzhou

Investment Director
Fosun Pharmaceutical Group
Shanghai City, China

Senior Associate
Blue Ocean Capital Group
Shenzhen, Guangdong, China
Ken X's Contact Information
Phone
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles

Find Emails
Access verified email addresses for your target contacts.
657M+ emails

Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers

More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.





